4-bromo-N-(3-cyano-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-benzamide | 302561-10-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-N-(3-cyano-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-benzamide
• 英文别名: 4-bromo-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)benzamide
• CAS: 302561-10-0
• 化学式: C₁₆H₁₃BrN₂OS
• mdl: MFCD00414715
• 分子量: 361.262
• InChiKey: MATLRAQBZJFRSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环己酮 在 sulfur 作用下， 以 吡啶 为溶剂， 反应 2.42h， 生成 4-bromo-N-(3-cyano-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-benzamide
  参考文献：
  名称：

  Synthesis and Anti‐Inflammatory Activity of 2‐Amino‐4,5,6,7‐tetrahydrobenzo[ b ]thiophene‐Derived NRF2 Activators

  摘要：

  AbstractThis is the first study investigating the nuclear factor (erythroid‐derived 2)‐like 2 (NRF2) activity of compounds containing a new scaffold, tetrahydrobenzo[b]thiophene. Eighteen compounds were synthesised and confirmed their NRF2 activation through NQO1 enzymatic activity and mRNA expression of NQO1 and HO‐1 in Hepa‐1c1c7 cells. The compounds disrupted the interaction between Kelch‐like ECH‐associated protein 1 (KEAP1) and NRF2 via interfering with the KEAP1’s Kelch domain. The compounds exhibited anti‐inflammatory activity in Escherichia coli Lipopolysaccharide (LPSEc)‐stimulated RAW 264.7 cells. The anti‐inflammatory activity of the compounds was associated with their ability to activate NRF2. The compounds reversed the elevated levels of pro‐inflammatory cytokines (IL‐1β, IL‐6, TNF‐α, and IFN‐γ) and inflammatory mediators (PGE2, COX‐2, and NF‐κB). The compounds were metabolically stable in human, rat, and mouse liver microsomes and showed optimum half‐life (T1/2) and intrinsic clearance (Clint). The binding mode of the compounds and physicochemical properties were predicted via in silico studies.

  DOI：

  10.1002/open.202200181

文献信息

• Cell migration inhibiting compositions and methods and compositions for treating cancer
  申请人：Edwards L. David

  公开号：US20060128742A1

  公开（公告）日：2006-06-15

  Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.

  本文提供了治疗癌症患者的方法。该方法可包括向患者施用细胞迁移抑制剂和化疗药物，以抑制癌细胞的迁移。抑制细胞迁移可增加细胞分裂。这样，由于细胞分裂增加，细胞迁移抑制剂和化疗剂联合使用的疗效可能比单独使用化疗剂的疗效更好。细胞迁移抑制剂可包括本文所述的任何抑制剂。例如，细胞迁移抑制剂可以是分子量小于约 700 的有机分子、单克隆抗体或天然产物。
• CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER
  申请人：Avolix Pharmaceuticals

  公开号：EP1576110A2

  公开（公告）日：2005-09-21
• EP1576110A4
  申请人：——

  公开号：EP1576110A4

  公开（公告）日：2007-11-07
• US7012100B1
  申请人：——

  公开号：US7012100B1

  公开（公告）日：2006-03-14
• US7700615B2
  申请人：——

  公开号：US7700615B2

  公开（公告）日：2010-04-20